- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07841847
Effects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease
Changes in Specific miRNAs and Biochemical Biomarkers Following Personalized Cardiac Rehabilitation in Patients With Coronary Artery Disease
This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Vural KAVUNCU, Prof. Dr.
- Numéro de téléphone: 90 505 777 43 06
- E-mail: vural.kavuncu@ksbu.edu.tr
Sauvegarde des contacts de l'étude
- Nom: Meltem ÇOBAN, Dr.
- Numéro de téléphone: +90 544 284 42 58
- E-mail: meltem.368@hotmail.com
Lieux d'étude
-
-
-
Kütahya, Turquie (Türkiye), 43020
- Kutahya Health Sciences University
-
Contact:
- Vural KAVUNCU, Prof. Dr.
- Numéro de téléphone: 1111 02742630043
- E-mail: vural.kavuncu@ksbu.edu.tr
-
Chercheur principal:
- Fatima YAMAN, Assoc. Prof
-
Chercheur principal:
- Meltem ÇOBAN, Dr.
-
Sous-enquêteur:
- Merve AKDENİZ LEBLEBİCİER, Assoc. Prof
-
Sous-enquêteur:
- Mevlüt DEMİR, Assoc. Prof
-
Sous-enquêteur:
- Cansu OZBAYER, Prof. Dr.
-
Sous-enquêteur:
- Fatih KAR, Assoc. Prof.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Stable coronary artery disease
- History of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
- Referred and considered clinically eligible for a structured cardiac rehabilitation program
- Achievement of a respiratory quotient (RQ) of at least 1.0 during the baseline cardiopulmonary exercise test
- Ability and willingness to participate in the study and complete the cardiac rehabilitation program
Exclusion Criteria:
- Symptoms or signs of myocardial ischemia
- Significant left ventricular outflow tract obstruction
- Ventricular arrhythmia
- Significant valvular heart disease
- Uncontrolled hypertension
- Severe comorbid conditions, including end-stage renal disease, advanced liver disease, or chronic inflammatory disease
- Active malignancy
- Physical limitations preventing full participation in exercise, including severe musculoskeletal disorders or major orthopedic or neurological comorbidities
- Body mass index greater than 35 kg/m²
- History of orthopedic surgery within the previous 6 months
- Failure to comply with exercise testing or training procedures, or attendance of less than 80% of the rehabilitation program
- Use of medications known to directly alter miRNA expression, such as certain immunosuppressive agents or chemotherapy drugs
- Known psychiatric disorder
- Presence of a permanent cardiac pacemaker
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Personalized Cardiac Rehabilitation Group
Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program. |
Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in miRNA Expression Levels
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Peak Oxygen Uptake (VO₂max)
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Maximum Exercise Workload
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Six-Minute Walk Test Distance
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Resting Heart Rate
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Maximum Heart Rate
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
|
Change in Health-Related Quality of Life
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program. |
Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Vural KAVUNCU, Prof. Dr., Kutahya Health Sciences University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- KSBÜ-CR-miRNA-
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
"Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .